Basiliximab induction alone vs a dual ATG-basiliximab approach in first live-donor non-sensitized kidney transplant recipients with low HLA matching.

Tammy HodShmuel LevingerEnosh AskenasyMaya Siman-TovYana DavidovRonen GhineaNiv PencovichIdo NachmaniEytan Mor

Published in: Clinical kidney journal (2024)

In non-sensitized first live-donor KTRs with low HLA matching, a dual ATG-basiliximab induction approach significantly reduced early ACR without compromising safety.

Keyphrases